Phase 3 eVOLVE-Lung02 Trial of Volrustomig plus Chemotherapy (CT) vs Pembrolizumab plus CT in Metastatic NSCLC With PD-L1 TC <50%

Authors

• M. L. Johnson
• E. Arriola
• T. Kato
• N. Girard
• Shirish M. Gadgeel, Henry Ford HealthFollow
• M. Majem Tarruella
• T. Newsom-Davis
• M. Polaczek
• X. Chen
• K. Stefaniak
• C. Lowery
• N. Angra
• G. Doherty
• M-J. Ahn

Recommended Citation

Johnson ML, Arriola E, Kato T, Girard N, Gadgeel SM, Majem Tarruella M, Newsom-Davis T, Polaczek M, Chen X, Stefaniak K, Lowery C, Angra N, Doherty G, Ahn M. Phase 3 eVOLVE-Lung02 Trial of Volrustomig plus Chemotherapy (CT) vs Pembrolizumab plus CT in Metastatic NSCLC With PD-L1 TC <50%. J Thorac Oncol 2025; 20(10):1.

Document Type

Conference Proceeding

Publication Date

10-1-2025

Publication Title

J Thorac Oncol

Keywords

Oncology, Respiratory System

Volume

20

Issue

10

First Page

1